Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

Introduction  In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were not included in the primary analysis. This study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorana, Alok A., McNamara, Mairéad G., Kakkar, Ajay K., Streiff, Michael B., Riess, Hanno, Vijapurkar, Ujjwala, Kaul, Simrati, Wildgoose, Peter, Soff, Gerald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245534/
https://www.ncbi.nlm.nih.gov/pubmed/32462111
http://dx.doi.org/10.1055/s-0040-1712143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245534/
https://www.ncbi.nlm.nih.gov/pubmed/32462111
http://dx.doi.org/10.1055/s-0040-1712143

Ejemplares similares